Epizyme, Inc.
Clinical trials sponsored by Epizyme, Inc., explained in plain language.
-
New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial
Disease control OngoingThis study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…
Phase: PHASE3 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Cancer drug trial for lymphoma patients without key mutation pulled before start
Disease control TerminatedThis was a phase 2 study testing the oral drug tazemetostat in adults with relapsed or refractory follicular lymphoma whose tumors lack an EZH2 gain-of-function mutation. The drug is already approved for this cancer, but researchers wanted to see how well it works in this specifi…
Phase: PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC